Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study
- 15 November 2011
- journal article
- research article
- Published by Taylor & Francis in AIDS Care
- Vol. 24 (4) , 478-490
Abstract
In this study, we investigated the causes of death and the factors associated with mortality in a cohort of patients receiving highly active antiretroviral therapy (HAART) in Burkina Faso, an African country with limited resources. This retrospective cohort study included patients aged 15 years and older who started HAART for the first time between January 2003 and December 2008 in 14 health districts. We used survival analyses, including the Kaplan–Meier method, to examine potential predictors of death and two Cox proportional hazard models to estimate hazard ratios for death, first from baseline covariates and then from time-dependent covariates. A total of 6641 patients initiated HAART during this period; of these, 5608 were included in the analysis. By the end of the study period, 4310 of those patients were still receiving HAART, 690 had died, 207 had been transferred and 401 were lost to follow-up. The median duration of follow-up was 23.2 months [interquartile range (IQR): 12.4–36.9], and the overall incidence of mortality was 6 per 100 person-years. The clinical stage, CD4 count, body mass index (BMI), haemoglobin level, HAART regimen, gender, age, profession and year of initiation were the primary risk factors associated with death. In the multivariate analysis, BMI, clinical stage, treatment regimen and CD4 count remained significantly associated with death. The most frequent causes of death were wasting syndrome, tuberculosis and anaemia. This result highlights the already advanced stage of immunodeficiency among patients in Burkina Faso when they start HAART. Testing patients for HIV and starting antiretroviral therapy earlier are necessary to further reduce the mortality of patients living with HIV. This study provides a solid evidence base with which future evaluations of HAART in Burkina Faso can be compared.Keywords
This publication has 23 references indexed in Scilit:
- Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/μl is associated with improved treatment outcomes in South AfricaAIDS, 2010
- Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina FasoTransactions of the Royal Society of Tropical Medicine and Hygiene, 2010
- CD4+ Response and Subsequent Risk of Death Among Patients on Antiretroviral Therapy in Lusaka, ZambiaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South AfricaAIDS, 2009
- Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan AfricaAIDS, 2008
- Change over time of mortality predictors after HAART initiation in a Senegalese cohortEuropean Journal of Epidemiology, 2008
- Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West AfricaAIDS, 2007
- A 84‐month follow up of adherence to HAART in a cohort of adult Senegalese patientsTropical Medicine & International Health, 2007
- True outcomes for patients on antiretroviral therapy who are lost to follow-up in Malawi2007
- Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studiesAIDS, 2007